P

Assignee

GENENTECH INC

US2,896 patents

Top patents by PatentIndex Score

US7862817B2Jan 4, 2011

Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies

GENENTECH INC126 citations99
US7695936B2Apr 13, 2010

Knobs and holes heteromeric polypeptides

GENENTECH INC817 citations99
US7666413B2Feb 23, 2010

Method of reducing viscosity of high concentration protein formulations

GENENTECH INC103 citations99
US7642228B2Jan 5, 2010

Method for making heteromultimeric polypeptides

GENENTECH INC404 citations99
US7560111B2Jul 14, 2009

HER2 antibody composition

GENENTECH INC122 citations99
US7537931B2May 26, 2009

Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies

GENENTECH INC83 citations99
US7501122B2Mar 10, 2009

Treatment with anti-ErbB2 antibody combinations

GENENTECH INC76 citations99
US7498030B2Mar 3, 2009

Treatment with anti-ErbB2 antibodies and anti-hormonal compounds

GENENTECH INC69 citations99
US7485302B2Feb 3, 2009

Treatment with anti-ErbB2 antibodies and chemotherapeutic agents

GENENTECH INC109 citations99
US7416727B2Aug 26, 2008

Polypeptide variants with altered effector function

GENENTECH INC89 citations99
US7371826B2May 13, 2008

Polypeptide variants with altered effector function

GENENTECH INC1,099 citations99
US7335742B2Feb 26, 2008

Polypeptide variants with altered effector function

GENENTECH INC167 citations99
US7332581B2Feb 19, 2008

Polypeptide variants with altered effector function

GENENTECH INC1,197 citations99
US7183387B1Feb 27, 2007

Polypeptide variants with altered effector function

GENENTECH INC223 citations99
US7169901B2Jan 30, 2007

Anti-VEGF antibodies

GENENTECH INC160 citations99
US7122637B2Oct 17, 2006

Polypeptide variants with altered effector function

GENENTECH INC188 citations99
US7060269B1Jun 13, 2006

Anti-VEGF antibodies

GENENTECH INC342 citations99
US6998253B1Feb 14, 2006

Altered polypeptides with increased half-life

GENENTECH INC250 citations99
US6949245B1Sep 27, 2005

Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies

GENENTECH INC317 citations99
US6916648B2Jul 12, 2005

Secreted and transmembrane polypeptides and nucleic acids encoding the same

GENENTECH INC90 citations99
US6884879B1Apr 26, 2005

Anti-VEGF antibodies

GENENTECH INC623 citations99
US6875432B2Apr 5, 2005

Reduced-viscosity concentrated protein formulations

GENENTECH INC316 citations99
US6800738B1Oct 5, 2004

Method for making humanized antibodies

GENENTECH INC274 citations99
US6737056B1May 18, 2004

Polypeptide variants with altered effector function

GENENTECH INC3,376 citations99
US6719971B1Apr 13, 2004

Method for making humanized antibodies

GENENTECH INC393 citations99
US6639055B1Oct 28, 2003

Method for making humanized antibodies

GENENTECH INC523 citations99
US6635468B2Oct 21, 2003

Secreted and transmembrane polypeptides and nucleic acids encoding the same

GENENTECH INC92 citations99
US6582959B2Jun 24, 2003

Antibodies to vascular endothelial cell growth factor

GENENTECH INC283 citations99
US6451561B1Sep 17, 2002

Growth hormone variants

GENENTECH INC96 citations99
US6451764B1Sep 17, 2002

VEGF-related protein

GENENTECH INC143 citations99
US6407213B1Jun 18, 2002

Method for making humanized antibodies

GENENTECH INC2,158 citations99
US6399063B1Jun 4, 2002

Monoclonal antibodies directed to the HER2 receptor

GENENTECH INC282 citations99
US6387371B1May 14, 2002

Monoclonal antibodies directed to the HER2 receptor

GENENTECH INC272 citations99
US6342369B1Jan 29, 2002

Apo-2-receptor

GENENTECH INC127 citations99
US6172213B1Jan 9, 2001

Anti-IgE antibodies and method of improving polypeptides

GENENTECH INC155 citations99
US6165464ADec 26, 2000

Monoclonal antibodies directed to the HER2 receptor

GENENTECH INC363 citations99
US6153189ANov 28, 2000

Human TRK receptors and neurotrophic factor inhibitors

GENENTECH INC165 citations99
US6121022ASep 19, 2000

Altered polypeptides with increased half-life

GENENTECH INC1,223 citations99
US6096871AAug 1, 2000

Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

GENENTECH INC290 citations99
US6054297AApr 25, 2000

Humanized antibodies and methods for making them

GENENTECH INC2,266 citations99
US6037453AMar 14, 2000

Immunoglobulin variants

GENENTECH INC180 citations99
US6037454AMar 14, 2000

Humanized anti-CD11a antibodies

GENENTECH INC183 citations99
US6027927AFeb 22, 2000

Human trk receptors and neurotrophic factor inhibitors

GENENTECH INC137 citations99
US6022711AFeb 8, 2000

Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1

GENENTECH INC100 citations99
US6013478AJan 11, 2000

Method for identifying active domains and amino acid residues in polypeptides and hormone variants

GENENTECH INC184 citations99
US5994511ANov 30, 1999

Anti-IgE antibodies and methods of improving polypeptides

GENENTECH INC210 citations99
US5910574AJun 8, 1999

Human trk receptors and neurotrophic factor inhibitors

GENENTECH INC140 citations99
US5877016AMar 2, 1999

Human trk receptors and neurotrophic factor inhibitors

GENENTECH INC190 citations99
US5869046AFeb 9, 1999

Altered polypeptides with increased half-life

GENENTECH INC2,474 citations99
US5844092ADec 1, 1998

Human TRK receptors and neurotrophic factor inhibitors

GENENTECH INC219 citations99

Showing the top 50 of 2,896 patents by PatentIndex Score.